LOGIN  |  REGISTER
FILTER BY TOPIC:     Enrollment   Pre-Clinical   First Dose   Phase 1   Phase 1/2   Phase 2   Phase 2/3   Phase 3  

Ocugen Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy...

July 18
Last Trade: 1.00 0.002 0.20

MALVERN, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the first patient has been dosed in its Phase 2/3 GARDian3 clinical trial for...Read more


Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients...

July 18
Last Trade: 47.36 -0.70 -1.46

PRINCETON, N.J. / Jul 18, 2025 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 INDEPENDENCE trial evaluating Reblozyl® (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with myelofibrosis-associated anemia...Read more


Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

July 18
Last Trade: 8.88 -0.39 -4.21

PITTSBURGH, July 18, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in...Read more


Genentech Provides Update on Supplemental Biologics License Application for Columvi Combination for People With Relapsed...

July 18
Last Trade: 40.06 -0.14 -0.35

SOUTH SAN FRANCISCO, Calif. / Jul 18, 2025 / Business Wire / Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for Genentech’s supplemental Biologics License Application (sBLA)...Read more


Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer

July 17
Last Trade: 163.70 0.72 0.44

New Drug Application supported by results from the Phase 2b SunRISe-1 study RARITAN, N.J., July 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) granted Priority Review to the New Drug Application (NDA) filed for...Read more


Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures...

July 17
Last Trade: 53.85 -1.07 -1.95

The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The EMBOLD cohort 2 pivotal trial is on track for topline results in H1 2026 with NDA filing to...Read more


Featured Stock

Recursion

Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...

CLICK TO LEARN MORE

Biggest Gainers

 
CompanyChangeLast Trade
Eli Lilly 11.43 1.50 $772.94
CRISPR Therapeutics 10.11 18.35 $65.20
Veeva Systems 5.83 2.11 $282.29
Bolt Biotherapeutics 4.97 887.50 $5.53
Cyclacel Pharmaceuticals 4.57 55.53 $12.80
Cidara Therapeutics 3.77 6.71 $59.96
Mesoblast 3.33 26.99 $15.67
Abbott 3.16 2.62 $123.67
Nutex Health 3.03 2.74 $113.81
Intuitive 2.46 0.48 $518.62
Tarsus Pharmaceuticals 1.85 4.47 $43.25
Merus 1.82 2.96 $63.26
Ligand Pharmaceuticals 1.53 1.11 $139.10
ResMed 1.50 0.58 $257.92
MEI Pharma 1.45 32.22 $5.95
RAPT Therapeutics 1.45 14.17 $11.68
PureTech Health 1.17 6.32 $19.67
Eton Pharmaceuticals 1.09 7.82 $15.02

Highest Volume

 
CompanyVolumeLast Trade
Incannex Healthcare 462,409,334 $0.65
Telomir Pharmaceuticals 135,310,719 $2.28
Healthcare Triangle 114,250,306 $0.02
Sarepta Therapeutics 75,535,509 $14.06
NuCana 64,589,035 $0.05
Oscar Health 64,410,901 $13.41
53,032,415 $5.85
MEI Pharma 41,046,545 $5.95
Pfizer 32,867,328 $24.47
Centene 22,281,880 $27.90
Cyclacel Pharmaceuticals 22,092,607 $12.80
Windtree Therapeutics 18,973,361 $1.19
Abbott 17,371,092 $123.67
Senseonics 15,619,626 $0.58
Iovance Biotherapeutics 14,668,113 $2.23
UnitedHealth 14,195,974 $282.58
Atai Life Sciences 14,119,465 $3.23
Teva Pharmaceutical 11,847,977 $16.06
AbCellera Biologics 11,515,121 $4.51
  • Upcoming FDA Catalysts

    • Ascendis Pharma (NASDAQ: ASND) PDUFA Date

      July 27, 2025
    • Apellis Pharmaceuticals (NASDAQ: APLS) PDUFA Date

      July 28, 2025
    • Regeneron Pharmaceuticals (NASDAQ: REGN) PDUFA Date

      July 30, 2025
    • Tonix Pharmaceuticals (NASDAQ: TNXP) PDUFA Date

      August 15, 2025
    • Ultragenyx Pharmaceutical (NASDAQ: RARE) PDUFA Date

      August 18, 2025
    • PTC Therapeutics (NASDAQ: PTCT) PDUFA Date

      August 19, 2025

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Surmodics

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...

CLICK TO LEARN MORE

Invest In Early-Stage Biotech Opportunities

  • Explore venture capital investment opportunities in the healthcare industry and gain direct access to deal flows

  • Private placement shares can generally be purchased at a discount to market prices and have purchase warrants attached to them

  • If the underlying share price rises, warrants can be exercised to further build positions and enhance gains

  • Sign up to receive notifications of future early-stage investment opportunities: